The clinical experience of netromycin use in complex antibacterial therapy of adult patients with cystic fibrosis

Abstract

The present study shows results of use of aminoglycoside antibiotic netylmycin (Netromycin — ScheringPlough, USA) со-administered with a complex therapy in 12 adult cystic fibrosis patients.
The antibacterial therapy efficacy was evaluated according to the following criteria: clinical state dynamics according to Schwachman score, chest radiography dynamics, lung function testing dynamics and sputum microbiological examination. The sensitivity of microorganisms for Netromycin was detected by disk-diffusion method.
Netromycin was administered in a daily dose of 10mg/kg of body weight intravenously twice a day for 14 days in a combination with cephalosporines of the 3-rd generation.
The positive clinical effect was reached in 11 patients. The clinical stabilisation was obtained in 1 case. The microorganisms colonies number was reduced to single ones in 11 patients and it was confirmed microbiologically.
The drug was well tolerated without any adverse events if used in the doses mentioned above.
Thus, the present study has demonstrated that Netromycin in a daily dose of 10 mg/kg of body weight combined with cephalosporines of the 3-rd generation is effective drug and it could be recommended for treatment of adult cystic fibrosis patients.